CAS: 888958-27-8

SARS-CoV-IN-3 is a small-molecule inhibitor, which is derived through synthetic organic chemistry targeting SARS-CoV-2. It exhibits its mode of action by specifically inhibiting the viral RNA-dependent RNA polymerase (RdRp) enzyme. This enzyme is crucial for viral RNA synthesis, and by inhibiting its activity, SARS-CoV-IN-3 effectively suppresses viral replication within host cells. The applications of SARS-CoV-IN-3 are primarily in the context of antiviral research, particularly focusing on mechanistic studies of coronavirus replication and potential therapeutic interventions. Its ability to target and inhibit a key viral enzyme makes it a valuable tool for understanding the lifecycle of the virus and for exploring new avenues in antiviral drug development. Scientists utilize SARS-CoV-IN-3 to dissect the pathways involved in viral transcription and replication, contributing to the broader field of infectious disease research and the potential development of therapeutic agents aimed at treating SARS-CoV-2 infections.

SARS-CoV-IN-3 is an effective SARS-CoV replication inhibitor.